LBRX
LB PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$38.81
+5.63%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+26.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 13, 2026 | Miller Joseph M · officer: Chief Financial Officer | A-Award | 200,000 | $37 |
| Oct 13, 2026 | Kozauer Susan Gani · officer: Chief Medical Officer | A-Award | 200,000 | $37 |
Institutional positioning
13F filings over the trailing two quarters
New 65Increased 70Reduced 30Sold out 3
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Deep Track Capital, LP | Unchanged | 3,352,804 | Aug 14, 2026 |
| DEEP TRACK CAPITAL, LP | Unchanged | 3,352,804 | May 15, 2026 |
| BlackRock, Inc. | Increased | 2,734,305 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 2,470,845 | May 13, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 2,208,604 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 2,208,604 | Aug 14, 2026 |
| TCG CROSSOVER MANAGEMENT, LLC | Increased | 1,839,489 | May 15, 2026 |
| Trails Edge Capital Partners, LP | Increased | 1,523,022 | Aug 14, 2026 |
| COMMODORE CAPITAL LP | Unchanged | 1,500,000 | May 15, 2026 |
| Commodore Capital LP | Unchanged | 1,500,000 | Aug 14, 2026 |
| JPMORGAN CHASE & CO | Increased | 1,497,293 | Aug 12, 2026 |
| TCG Crossover Management, LLC | Reduced | 1,447,310 | Aug 14, 2026 |
| Caligan Partners LP | Unchanged | 1,438,070 | Aug 14, 2026 |
| CALIGAN PARTNERS LP | New Position | 1,438,070 | May 15, 2026 |
| JPMORGAN CHASE & CO | Reduced | 1,427,568 | May 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 13, 2026